Orum Therapeutics
Min Soo Kim has a diverse work experience in the field of Antibody Engineering. Min Soo started their career as a Scientist at GC Biopharma in 2008 and worked there until 2012. After that, they joined MOGAM Institute for Biomedical Research and held the position of Senior Scientist from 2013 to 2016. In 2016, Min Soo Kim transitioned to CJ HealthCare Corp. where they worked as a Principal Scientist for three years. Their most recent role is at Orum Therapeutics, where they are currently serving as the Director of Antibody Engineering since July 2019.
Min Soo Kim is a PhD candidate in Antibody Engineering at Ajou University. Prior to pursuing this degree, they completed their Master of Science in Antibody Engineering at the same institution from 2006 to 2008. Min Soo Kim also holds a Bachelor of Science degree in the Department of Biological Engineering, which they earned from Ajou University from 1998 to 2006.
This person is not in any offices
Orum Therapeutics
Orum Therapeutics is a private biotech company developing a new class of therapeutic antibodies targeting cytosolic proteins for unmet medical needs in cancer and rare diseases. Orum leverages its unique cell-penetrating antibody platform, called Oromab™ to inhibit drug targets, previously undruggable by small molecules or current antibodytherapeutics. In contrast to other approaches, Orum’s antibody platform can intracellularly deliver an active antibody therapeutic or payload, is easily adaptable to target different cell types and intracellular proteins, and does not require chemical modification.